Titlebook: Recent Advances and Future Directions in Bone Marrow Transplantation; Proceedings of a Sym Siegmund J. Baum,George W. Santos (Professor of

caldron

Hematopoietic Cell Transplantation in Murine Globoid Cell Leukodystrophy (The Twitcher Mouse)—A Modeymptomatic supportive care. Allogeneic bone marrow transplantation (BMT) may be therapeutic in these disorders by repopulating the lymphohematopoietic and reticuloendothelial systems with enzymatically normal donor-derived cells, thus providing a stable, self-renewing source of enzyme(s) in which th

Acumen

Experimental Basis of Bone Marrow Purging with Chemical and Photodynamic Agentsossibly due to occult leukemic cells contaminating the remission marrow. Although the efficacy of the ex-vivo purging procedure has yet to be definitely established in clinical practice, there are indications that cleansing the marrow is associated with improved survival in some cases (1, 2). To mee

淡紫色花

Oncogenes in Acute Myelogenous Leukemia analogues of cellular proto-oncogenes in the context of acutely transforming retroviruses, is responsible for neoplastic transformation. Possible mechanisms by which viral or cellular oncogenes can cause neoplastic transformation have been recently reviewed (2,3). Since qualitative and quantitative

enchant

Optimal Timing of Marrow Transplantation for Patients with Acute Nonlymphoblastic and Acute Lymphoblastic leukemia (ALL). However, the optimal time for intervention in a patient’s disease course with marrow transplantation is yet to be determined. The following will briefly review the current situation.

合適

夾克怕包裹

Allogeneic and Autologous Marrow Transplants in Acute Nonlymphoblastic Leukemia (ANLL) (1–4). Problems with marrow transplantation such as leukemia relapse, graft-versus-host disease (GVHD) and viral infections have been identified and solutions to these problems are being actively pursued in many centers around the world.

紡織品

Allogeneic Transplantation for Acute Lymphoblastic Leukemiao exceed 2000 allografts and possibly up to 1000 autografts.(1) It is therefore possible to define the success of transplant procedures in some detail and to determine the best treatment option for the individual patient with ALL. This becomes increasingly important with the emergence of improved ch

蟄伏

我不死扛

Comedienne

Allogeneic Bone Marrow Transplantation for Leukemia—Japanese Experience in 1980 after the formation of the Japan BMT study group of 31 hospitals supported by a grant from the Ministry of Health and Welfare of Japan. This paper reports the data obtained from the registry of the Japanese study group. Member hospitals are listed in Table 1.